Barclays PLC boosted its stake in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) by 25.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,054 shares of the company’s stock after purchasing an additional 624 shares during the period. Barclays PLC’s holdings in Kiniksa Pharmaceuticals were worth $86,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of the stock. Legal & General Group Plc bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $25,000. Strs Ohio lifted its stake in Kiniksa Pharmaceuticals by 157.9% in the 4th quarter. Strs Ohio now owns 4,900 shares of the company’s stock valued at $137,000 after purchasing an additional 3,000 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Kiniksa Pharmaceuticals by 20.5% in the 4th quarter. Bank of New York Mellon Corp now owns 20,570 shares of the company’s stock valued at $578,000 after purchasing an additional 3,499 shares during the last quarter. New York State Common Retirement Fund bought a new position in Kiniksa Pharmaceuticals in the 4th quarter valued at approximately $107,000. Finally, American International Group Inc. bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $110,000. 23.05% of the stock is owned by institutional investors and hedge funds.
NASDAQ KNSA traded up $0.91 on Friday, hitting $15.50. The company’s stock had a trading volume of 83,979 shares, compared to its average volume of 142,193. Kiniksa Pharmaceuticals Ltd has a 1-year low of $13.04 and a 1-year high of $32.88. The stock has a market cap of $811.13 million and a P/E ratio of -4.44.
Several brokerages recently commented on KNSA. Zacks Investment Research downgraded shares of Kiniksa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 10th. Barclays assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Monday, March 11th. They issued an “overweight” rating and a $26.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Kiniksa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $31.00.
Kiniksa Pharmaceuticals Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Featured Story: Fiduciary
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.